Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. It is the first and only FDA-approved, PSMA-targeted imaging agent developed with proprietary radiohybrid (rh) technology.

Diagnostic 97

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 97

Imaging Technology

JULY 28, 2023

POSLUMA is widely available through 36 radiopharmacies in the national network of Blue Earth Diagnostics’ commercial U.S. The addition of POSLUMA to the highly respected NCCN Guidelines is a major milestone for Blue Earth Diagnostics,” said David E. Chief Medical Officer of Blue Earth Diagnostics. Teoh, MBBS, MRCP, FRCR, D.Phil.,

Diagnostic 98

Diagnostic Clinic Radiopharmaceuticals Radiation 98

AuntMinnie

MARCH 15, 2024

However, increased longevity has brought on a troubling rise in chronic disease, diminishing the quality of life later in life. A 2018 study from the U.S. Centers for Disease Control and Prevention (CDC) found that more than a quarter of U.S. Mark Crockett, MD, chief medical officer at TeleDaaS.

Radiopharmaceuticals 105

Radiopharmaceuticals Radiation Disease Diagnostic Imaging 105

Vesta Teleradiology

FEBRUARY 3, 2024

Like the general populace, prevalent causes of mortality within Native American communities encompass heart disease, cancer, and accidents. They advocate for strategies to address this shortage and ensure that American Indians, Alaska Natives, and Native Hawaiians receive adequate healthcare.

Healthcare 52

Healthcare Healthcare Teleradiology Disease 52

AuntMinnie

MARCH 26, 2024

Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. Lutathera was approved for adults by the FDA in 2018 after the therapy resulted in progression-free survival (median overall survival of 11.7

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

Imaging Technology

OCTOBER 5, 2023

Effective initial staging of prostate cancer, particularly with regards to the detection of metastatic disease, is critical to optimal clinical management of patients,” said Phillip H. Kuo, MD, Ph.D. , Departments of Medical Imaging, Medicine, and Biomedical Engineering. Chief Executive Officer of Blue Earth Diagnostics.

Diagnose 52

Diagnose Diagnostic Disease Radiation 52

AuntMinnie

JUNE 20, 2024

Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. Lutathera was approved for adults by the FDA in 2018 after the therapy resulted in progression-free survival (median overall survival of 11.7

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52